Market Cap 88.62M
Revenue (ttm) 5.72M
Net Income (ttm) -75.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,318.36%
Debt to Equity Ratio 0.00
Volume 100,700
Avg Vol 876,472
Day's Range N/A - N/A
Shares Out 47.90M
Stochastic %K 50%
Beta 1.89
Analysts Sell
Price Target $2.31

Company Profile

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically val...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 900 4690
Address:
500 West 5th Street, Suite 1200, Austin, United States
NyseDayTrader
NyseDayTrader Oct. 21 at 1:03 AM
$STTK nothing to see here. Just casually up 17%! 😉
0 · Reply
NyseDayTrader
NyseDayTrader Oct. 16 at 3:55 PM
$STTK small caps are hurting except...
0 · Reply
NyseDayTrader
NyseDayTrader Oct. 10 at 7:19 PM
$STTK in 1.87
0 · Reply
Lacuna_Reborn
Lacuna_Reborn Oct. 10 at 4:38 PM
Cut $STTK and $HUDI for small losses Market ruined technical setups. Still holding $MTNB
0 · Reply
Lacuna_Reborn
Lacuna_Reborn Oct. 10 at 2:18 PM
$STTK added more @ 2.13
0 · Reply
Lacuna_Reborn
Lacuna_Reborn Oct. 9 at 5:31 PM
$STTK adding more here if they let me execute the order
0 · Reply
Lacuna_Reborn
Lacuna_Reborn Oct. 8 at 10:48 PM
$STTK new position @ 2.42 avg
0 · Reply
grizzly3
grizzly3 Oct. 8 at 6:32 PM
Check $STTK chart - the same is going to happen here. Eventless spike. Better sell before too late. $FDMT
0 · Reply
peepthestamp
peepthestamp Oct. 7 at 10:54 PM
$BENF $BURU $EVEX $STSS $STTK - Aging well 👀
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 7 at 7:47 PM
$STTK just stumbled -3% lower to -1% (~1Mv) moments ago, 10/17 options, follow for more volatility.
0 · Reply
Latest News on STTK
NyseDayTrader
NyseDayTrader Oct. 21 at 1:03 AM
$STTK nothing to see here. Just casually up 17%! 😉
0 · Reply
NyseDayTrader
NyseDayTrader Oct. 16 at 3:55 PM
$STTK small caps are hurting except...
0 · Reply
NyseDayTrader
NyseDayTrader Oct. 10 at 7:19 PM
$STTK in 1.87
0 · Reply
Lacuna_Reborn
Lacuna_Reborn Oct. 10 at 4:38 PM
Cut $STTK and $HUDI for small losses Market ruined technical setups. Still holding $MTNB
0 · Reply
Lacuna_Reborn
Lacuna_Reborn Oct. 10 at 2:18 PM
$STTK added more @ 2.13
0 · Reply
Lacuna_Reborn
Lacuna_Reborn Oct. 9 at 5:31 PM
$STTK adding more here if they let me execute the order
0 · Reply
Lacuna_Reborn
Lacuna_Reborn Oct. 8 at 10:48 PM
$STTK new position @ 2.42 avg
0 · Reply
grizzly3
grizzly3 Oct. 8 at 6:32 PM
Check $STTK chart - the same is going to happen here. Eventless spike. Better sell before too late. $FDMT
0 · Reply
peepthestamp
peepthestamp Oct. 7 at 10:54 PM
$BENF $BURU $EVEX $STSS $STTK - Aging well 👀
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 7 at 7:47 PM
$STTK just stumbled -3% lower to -1% (~1Mv) moments ago, 10/17 options, follow for more volatility.
0 · Reply
NyseDayTrader
NyseDayTrader Oct. 6 at 7:10 PM
$STTK I've been watching this climb since $1.20. Sneaky little bastard. It has all the characteristics of a POP coming. Big insider buys triggered the up move
0 · Reply
Thess5
Thess5 Oct. 6 at 4:59 PM
$IMG About to fly!! Huge! $STTK $PROK $GPRO $ADCT
0 · Reply
Caresto
Caresto Oct. 3 at 12:01 AM
$STTK good job, @YFZ450, Congrats! Way to drive!
0 · Reply
YFZ450
YFZ450 Oct. 2 at 8:14 PM
$STTK been stuck here a while finally out! low vol likely dumps, gl holders!
0 · Reply
grizzly3
grizzly3 Oct. 2 at 4:09 PM
$STTK Pipeline & Clinical Phases SL‑325 - Preclinical → transitioning to clinical (Phase 1) DR3‑based bispecifics / next‑generation candidates - Preclinical / nomination stage SL‑172154 (discontinued / deprioritized) - Previously clinical Many therapeutics fail due to toxicity, immunogenicity, or lack of efficacy in humans despite promising preclinical data. Although the recent capital raise is sizable, unfavorable outcomes or delays may still force future raises and dilution. As a small‑cap biotech, STTK’s valuation may be more volatile and sentiment-sensitive. Negative news, delays, or broader biotech sector pullbacks could disproportionately affect it Dependency on SL‑325 success: Given the pivot, the company is highly dependent on the success of this single program. Failure or underperformance could be damaging
0 · Reply
peepthestamp
peepthestamp Oct. 2 at 3:40 PM
1 · Reply
PepCF
PepCF Sep. 26 at 5:23 PM
0 · Reply
StockArbitrage
StockArbitrage Sep. 26 at 2:10 AM
$STTK Recruiting https://helpresearch.com/medical-study/ca45440-2a-0x00000000000067d2
0 · Reply
Stochalicious
Stochalicious Sep. 23 at 6:42 PM
0 · Reply
Pratik2024
Pratik2024 Sep. 21 at 12:09 PM
$ADAP $IXHL $LOBO $MWYN $STTK MWYN for coming days
0 · Reply
Kelsi1004
Kelsi1004 Sep. 19 at 3:08 PM
$ADAP $IXHL $LOBO $MWYN $STTK Is MWYN again?
0 · Reply
FetchDog
FetchDog Sep. 18 at 9:22 PM
$STTK The stock has been pumped up so institutional investors can dump on the heads of retail investors (i.e. future bag holders). From the S-3, these investors will be selling 100% of their shares (including shares obtained after exercise of warrants): Orbimed Advisors (36,879,576 shares), Baker Bros.(17,415,356 shares), Coastlands Capital Partners (11,524,868 shares), Entities Affiliated with NEXTBio (7,683,244 shares). Other investors will be selling a large percentage of their shares (including shares obtained after exercise of warrants): Redmile Group (selling 8,195,460 of 16,948,943 shares), Prosight Management (selling 9,732,110 of 16,510,563 shares), Adage Capital Partners (selling 8,707,678 of 13,382,678 shares), etc. Exercise of warrants will increase share count by around 188% while bringing in little cash ($57 million).
0 · Reply